Skip to content
HomeLatest newsHealth & wellnessBy the numbers: Who gets lung cancer?
A female doctor in a lab coat pointing to an xray of lungs on a tablet while explaining something to two seated patients.

By the numbers: Who gets lung cancer?

Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Learn how Johnson & Johnson is dedicated to improving outcomes by integrating the company’s MedTech and Innovative Medicine expertise.

Share Article
share to

Lung cancer is—by far—the leading cause of all cancer deaths across the globe, with 1.8 million people dying from the disease each year. Part of the reason has to do with the fact that early symptoms mimic common respiratory illnesses, so people with lung cancer often aren’t diagnosed until their cancer has reached an advanced stage.

Also at play? The “typical” patient is no longer so typical. Smokers, in other words, aren’t the only people at risk. Anyone who has a family history of the disease or is exposed to secondhand smoke and air pollution is also vulnerable.

But advances in early detection and breakthrough treatments are helping improve lung cancer outcomes. For one, the American Cancer Society recently updated its screening guidelines, recommending that people between the ages of 50 and 80 who smoke or formerly smoked 20 or more packs a year get screened annually.

And when it comes to developing innovative treatments, Interventional Oncology at Johnson & Johnson is focused on integrating the company’s MedTech and Innovative Medicine expertise to deliver therapies directly into lung tumors via minimally invasive procedures.

For Lung Cancer Awareness Month, here’s a look at the prevalence, diagnosis and mortality rates of lung cancer worldwide—and how Johnson & Johnson is playing a role in improving the lives of patients.

Infographic of who gets lung cancer on a red and white background

More ways Johnson & Johnson is working to fight lung cancer

See how researchers are developing preventive approaches for early detection, creating new therapies and more.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.